Latest News

05

September 2018

iX Biopharma Ltd is pleased to announce the success of its Phase 2 multi-dose clinical study (“KET010”) for Wafermine, its sublingual ketamine wafer for pain management...

Read On

27

August 2018

iX Biopharma capped off its financial year ended 30 June 2018 by achieving several major milestones in its pharmaceutical and nutraceutical businesses...

Read On

Our Sublingual Technology

Sublingual wafer administration offers the convenience of use over oral delivery, circumventing the drug breakdown in liver or gastrointestinal tract. The technology also provides rapid absorption, achieving maximum desirable therapeutic effect in a non-invasive manner.

Read On

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com